Cardiologist questions new cholesterol drug enlicitide's market impact

Cardiologist Vishal Khetpal argues in STAT News that Merck's new cholesterol drug enlicitide, branded Lipfendra, likely won't change prescribing habits much, despite its mechanism. While it aims to lower LDL-C, Khetpal believes existing statin regimens are too entrenched for an immediate shift. This means you might not see it replacing your current meds anytime soon.